Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.

Given the efficacy of rifampicin for an important sub-group of those with cholestatic pruritus, adult patients, including those with jaundice, can be counselled that 95% of prescriptions are safe, and where hepatitis occurs, including at long latency, drug cessation appears effective.